Therapeutic Galectin (NASDAQ: GALT) recently received a number of price target changes and ratings updates:

• 05/25/2022 – Galectin Therapeutics is now covered by StockNews.com analysts. They put a “sell” mark on the stock.
• 05/17/2022 – Galectin Therapeutics is now covered by StockNews.com analysts. They put a “sell” mark on the stock.
• 05/17/2022 – Galectin Therapeutics has had its price target lowered by HC Wainwright analysts from $14.00 to $11.00. They now have a “buy” rating on the stock.
• 5/9/2022 – Galectin Therapeutics is now covered by StockNews.com analysts. They put a “sell” mark on the stock.
• 05/01/2022 – Galectin Therapeutics is now covered by StockNews.com analysts. They put a “sell” mark on the stock.
• 04/23/2022 – Galectin Therapeutics is now covered by StockNews.com analysts. They put a “sell” mark on the stock.
• 04/15/2022 – Galectin Therapeutics is now covered by StockNews.com analysts. They put a “sell” mark on the stock.
• 04/07/2022 – Galectin Therapeutics is now covered by StockNews.com analysts. They put a “sell” mark on the stock.
• 04/01/2022 – Galectin Therapeutics has had its “buy” rating reaffirmed by analysts at HC Wainwright.
• 03/30/2022 – Galectin Therapeutics is now covered by StockNews.com analysts. They put a “sell” mark on the stock.

Shares of Galectin Therapeutics rose $0.07 during Wednesday’s trading, hitting $1.26. The stock had a trading volume of 33,249 shares, compared to an average volume of 110,608. The company has a market capitalization of $74.83 million, a price-earnings ratio of -2.17 and a beta of 1.64. The stock has a fifty-day moving average price of $1.57 and a two-hundred-day moving average price of $1.98. Galectin Therapeutics Inc. has a 52-week low of $1.19 and a 52-week high of $4.40. The company has a current ratio of 3.51, a quick ratio of 4.63 and a debt ratio of 79.37.

Galectin Therapeutics (NASDAQ:GALT – Get Rating) last reported quarterly results on Monday, May 16. The company reported ($0.17) EPS for the quarter, missing analyst consensus estimates of ($0.15) by ($0.02). On average, stock analysts expect Galectin Therapeutics Inc. to post EPS of -0.75 for the current fiscal year.

A number of institutional investors and hedge funds have recently increased or reduced their stake in GALT. Ameritas Investment Company LLC increased its position in Galectin Therapeutics by 12.7% during the third quarter. Ameritas Investment Company LLC now owns 44,232 shares of the company worth $172,000 after purchasing an additional 5,000 shares in the last quarter. Northern Trust Corp increased its position in Galectin Therapeutics by 5.8% during the fourth quarter. Northern Trust Corp now owns 93,988 shares of the company worth $194,000 after buying an additional 5,168 shares in the last quarter. BlackRock Inc. increased its position in Galectin Therapeutics by 0.7% during the fourth quarter. BlackRock Inc. now owns 793,025 shares of the company worth $1,642,000 after purchasing an additional 5,443 shares in the last quarter. Benjamin F. Edwards & Company Inc. increased its position in Galectin Therapeutics by 25.5% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 29,615 shares of the company worth $61,000 after purchasing an additional 6,015 shares last quarter. Finally, Centaurus Financial Inc. increased its position in Galectin Therapeutics by 44.8% during the third quarter. Centaurus Financial Inc. now owns 22,614 shares of the company worth $88,000 after purchasing an additional 7,000 shares in the last quarter. Institutional investors and hedge funds hold 12.35% of the company’s shares.

Galectin Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the research and development of therapies for fibrotic diseases, cancer and other diseases. The Company’s lead product candidate is the galactoarabino-rhamnogalacturonan polysaccharide polymer belapectin (GR-MD-02) galectin-3, which is in a Phase III clinical trial for the treatment of hepatic fibrosis associated with fatty liver disease. and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.

Featured Articles

Get news and reviews for Galectin Therapeutics Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Galectin Therapeutics Inc and related companies with MarketBeat.com’s FREE daily email newsletter.